Companies
WuXi Biologics
RU-friendlyGlobal CDMO powerhouse — open-access biologics platform covering cell line development through Phase 1–3 and commercial manufacturing for 800+ integrated projects.
- Country
- China
- Revenue
- RMB 18.7B
- Employees
- ~14,000 emp
FDA GMP
GMP EU
NMPA GMP
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| market-access-commercial | ✓ | ✓ | ✓ | ✓ |
| therapeutics-platforms | ✓ | ✓ | — | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Revenue | RMB 21.8 billion (2025-12-31) | prnewswire.com · wuxibiologics.com |
| Revenue | RMB 11.8 billion (H1 2026) (2026-06-30) | prnewswire.com · wuxibiologics.com |
| Capacity | Over 260,000 L of bioreactor capacity with planned increases to exceed 580,000 L (2025-01-09) | wuxibiologics.com |
| Production site | 15 GMP-certified manufacturing facilities (2026-06-30) | wuxibiologics.com |
| Certification | 166 facility license approvals obtained; 100% success rate across 49 regulatory inspections (since 2017) by authorities including U.S. FDA, EU EMA, and NMPA (2026-08-31) | megaproject.com · wuxibiologics.com |
| Headcount | 14,705 employees globally (2026-06-30) | wuxibiologics.com |
Independent sources: megaproject.com · prnewswire.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biologics | therapeutics-platforms | Low | → |
| Bioproduction CDMO/CMO (biologics/ATMP/mRNA) | therapeutics-platforms | Low | → |
| Local manufacturing for market access | market-access-commercial | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.